KKR completes $9.9B purchase of Envision

Amy Baxter | | Health Exec | Policy & Regulations

Private equity firm KKR has completed its acquisition of Envision Healthcare Corporation for a deal valued at $9.9 billion. The deal was previously announced in June.

Envision, a physician-led services and post-acute care and ambulatory surgery services provider, is now a wholly owned subsidiary of KKR. Envision stockholders will receive $46 per share of Envision common stock under terms of the deal. The company’s stock ceased trading on the New York Stock Exchange Friday as KKR took Nashville, Tennessee-based Envision private.

Envision had merged with Amsurg in 2016, making the entity a major healthcare provider in the nation. KKR also originally considered entering into the deal with for-profit hospital giant HCA Healthcare to potentially purchase the ambulatory surgery business, AmSurg, but HCA was not involved in the final deal.

The deal underscores the high-level interest from private equity in the healthcare space. Over the last several years, the industry has seen an influx of private equity investors looking for ways to add value to healthcare companies of all types. This rising interest has also helped valuations in the space rise rapidly.

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Report: UnitedHealth under investigation by DOJ for Medicare Advantage upcoding
FDA approves first therapy for very rare lipid storage disorder
FDA announces Class I recall of Boston Scientific pacemakers—replacement may be necessary
FDA ends semaglutide shortage, closing the door on compounded Wegovy, Ozempic
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”